Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
25.03. | Optimind Pharma Corp: Optimind Pharma resuming at the open | 1 | Stockwatch | ||
OPTIMIND PHARMA Aktie jetzt für 0€ handeln | |||||
25.03. | Optimind Pharma Corp: Optimind enters LOI to acquire Monjin Interviews | 3 | Stockwatch | ||
25.03. | Optimind Pharma Corp.: Optimind Pharma Enters into Letter of Intent with Monjin to Acquire AI Business | 508 | Newsfile | Toronto, Ontario--(Newsfile Corp. - March 24, 2025) - Optimind Pharma Corp. (CSE: OMND) (the "Optimind" or the "Company") announces that it has entered into a non-binding letter of intent dated March... ► Artikel lesen | |
21.03. | Optimind Pharma Corp: Optimind Pharma halted at 10:41 a.m. PT | 1 | Stockwatch | ||
29.07.24 | Optimind Pharma Corp.: Optimind Pharma Closes Second Tranche of Private Placement | 189 | Newsfile | Toronto, Ontario--(Newsfile Corp. - July 29, 2024) - Optimind Pharma Corp. (CSE: OMND) ("Optimind" or the "Company") announces it has closed the second trance of its previously announced private placement.... ► Artikel lesen | |
08.07.24 | Optimind Pharma Corp.: Optimind Pharma Closes First Tranche of Private Placement | 404 | Newsfile | Toronto, Ontario--(Newsfile Corp. - July 8, 2024) - Optimind Pharma Corp. (CSE: OMND) ("Optimind" or the "Company") announces it has closed the first trance of its previously announced private placement.... ► Artikel lesen | |
03.07.24 | Optimind Pharma Corp.: Optimind Pharma - Private Placement | 668 | Newsfile | Toronto, Ontario--(Newsfile Corp. - July 3, 2024) - Optimind Pharma Corp. (CSE: OMND) (the "Optimind" or the "Company") announces a proposed private placement. The Company intends to issue up to 10... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
NOVO NORDISK | 56,64 | -3,20 % | Novo Nordisk und Eli Lilly: Sind das jetzt schon Kaufkurse oder lieber Finger weg? | Seit geraumer Zeit stehen die Aktien der beiden Pharmaschwergewichte Novo Nordisk und Eli Lilly unter Abgabedruck. Die Talfahrt brachte beide Aktien auf vermeintlich günstige Kursniveaus. Sind das jetzt... ► Artikel lesen | |
AURORA CANNABIS | 3,492 | -5,77 % | Aurora Cannabis Aktie: Ein neuer Lichtblick! | Der kanadische Cannabisproduzent positioniert sich durch internationale Markterschließung, technologische Innovation und solide Finanzlage für langfristiges Wachstum. Aurora Cannabis zieht weiterhin... ► Artikel lesen | |
CANOPY GROWTH | 0,750 | -11,24 % | Canopy Growth Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
DIGICANN VENTURES | 0,004 | 0,00 % | Digicann Ventures Inc: Digicann Ventures extends debentures | ||
WPD PHARMACEUTICALS | 0,060 | 0,00 % | CSE Bulletin: Consolidation - WPD Pharmaceuticals Inc. (WBIO) | le 23 décembre/December 2024
WPD Pharmaceuticals Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every twenty-five... ► Artikel lesen | |
SINOPHARM | 2,025 | +1,25 % | SINOPHARM (01099): ANNOUNCEMENT PRINCIPAL AUDITED ACCOUNTING DATA AND FINANCIAL INDICATORS OF SINOPHARM ACCORD FOR THE YEAR ENDED 31 DECEMBER 2024 | ||
INDIVA | 0,016 | -100,00 % | SNDL Inc.: SNDL Emerges as Canada's Leading Producer of Edibles with Indiva Acquisition | CALGARY, AB, Nov. 4, 2024 /CNW/ - SNDL Inc. (Nasdaq: SNDL) ("SNDL" or the "Company") announced today that, in the context of Indiva Limited's ("Indiva" and together... ► Artikel lesen | |
ASTRIA THERAPEUTICS | 3,360 | -18,45 % | Astria Therapeutics, Inc.: Astria Therapeutics beginnt Phase-3-Zulassungsstudie ALPHA-ORBIT zu Navenibart bei hereditärem Angioödem | -- Studie zum Nachweis der Wirksamkeit und Sicherheit der Verabreichung alle 3 und alle 6 Monate in einem 6-monatigen Behandlungszeitraum --
Astria Therapeutics, Inc. (Nasdaq: ATXS), ein biopharmazeutisches... ► Artikel lesen | |
CSPC PHARMA | 0,563 | -1,98 % | CSPC PHARMA (01093): NEXT DAY DISCLOSURE RETURNS | ||
TONIX PHARMACEUTICALS | 18,000 | +10,02 % | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting | TNX-102 SL is a sublingual formulation of cyclobenzaprine designed for transmucosal delivery and durable activity in treating fibromyalgia TNX-102 SL demonstrated statistically significant improvement... ► Artikel lesen | |
ORAMED PHARMACEUTICALS | 1,964 | +2,29 % | Oramed Aktie: Besorgniserregende Signale? | Die Oramed Pharmaceuticals Aktie verzeichnete am 22. Februar 2025 einen signifikanten Rückgang. Der Aktienkurs fiel um 3,15 Prozent auf 2,15 USD, was einem Minus von 0,07 USD gegenüber dem vorherigen... ► Artikel lesen | |
AXSOME THERAPEUTICS | 88,12 | -2,33 % | Axsome Therapeutics, Inc.: Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer's Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American ... | Late-breaking oral presentation of results from the positive pivotal ACCORD-2 Phase 3 trial of AXS-05 in Alzheimer's disease agitation Presentation featuring network meta-analysis of SYMBRAVO® versus... ► Artikel lesen | |
ADASTRA | 0,186 | -9,71 % | Adastra Holdings Ltd.: Adastra Holdings Announces New Director | Langley, British Columbia--(Newsfile Corp. - March 3, 2025) - Adastra Holdings Ltd. (CSE: XTRX) (FSE: D2EP) ("Adastra" or the "Company"), a leading cannabis processor and producer of two top Canadian... ► Artikel lesen | |
ACHIEVE LIFE SCIENCES | 1,776 | -12,94 % | Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2024 and Provides Update on the Cytisinicline Development Program | Reiterates Planned Cytisinicline NDA Submission Expected at the End of Q2 2025 Company to Host Conference Call at 8:30 AM EDT Today, Tuesday, March 11, 2025 SEATTLE and VANCOUVER, British... ► Artikel lesen | |
ALTIMMUNE | 3,285 | -9,70 % | Altimmune Aktie: Im Zwiespalt der Erwartungen? | Das biopharmazeutische Unternehmen durchlebt trotz vielversprechender Therapieansätze für Adipositas und MASH eine Phase hoher Kursschwankungen bei sinkenden Notierungen Altimmune zieht derzeit die... ► Artikel lesen |